LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

P. Nathan, R. Dummer, G.V. Long, P.A. Ascierto, H.A. Tawbi, C. Robert, P. Rutkowski, O. Leonov, C. Dutriaux, M. Mandala', P. Lorigan, P.F. Ferrucci, K.T. Flaherty, J.C. Brase, S. Green, T. Haas, A. Masood, E. Gasal, A. Ribas, D. Schadendorf

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science